{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:27:32Z","timestamp":1792783652522,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Public Health Service","award":["R01 GM110119"],"award-info":[{"award-number":["R01 GM110119"]}]},{"name":"Public Health Service","award":["R01 GM110038"],"award-info":[{"award-number":["R01 GM110038"]}]},{"name":"Public Health Service","award":["R21 NS067671"],"award-info":[{"award-number":["R21 NS067671"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.antiviral.2016.11.001","type":"journal-article","created":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T02:32:33Z","timestamp":1478313153000},"page":"51-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation"],"prefix":"10.1016","volume":"136","author":[{"given":"Ryan P.","family":"Bennett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla A.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger G.","family":"Ptak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie K.","family":"Mankowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Robert W.","family":"Buckheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Salter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo A.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.11.001_bib1","doi-asserted-by":"crossref","first-page":"34083","DOI":"10.1074\/jbc.C400235200","article-title":"APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein","volume":"279","author":"Alce","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.11.001_bib2","doi-asserted-by":"crossref","first-page":"e1500296","DOI":"10.1126\/sciadv.1500296","article-title":"Transcriptional regulation of APOBEC3 antiviral immunity through the CBF-beta\/RUNX axis","volume":"1","author":"Anderson","year":"2015","journal-title":"Sci. Adv."},{"key":"10.1016\/j.antiviral.2016.11.001_bib3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1742-4690-5-54","article-title":"Characterization of APOBEC3G binding to 7SL RNA","volume":"5","author":"Bach","year":"2008","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2016.11.001_bib4","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1128\/JVI.03494-12","article-title":"APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells","volume":"87","author":"Batisse","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.11.001_bib5","doi-asserted-by":"crossref","first-page":"e1000925","DOI":"10.1371\/journal.ppat.1000925","article-title":"The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex","volume":"6","author":"Bergeron","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2016.11.001_bib6","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1093\/nar\/gkq979","article-title":"Importance of the proline-rich multimerization domain on the oligomerization and nucleic acid binding properties of HIV-1 Vif","volume":"39","author":"Bernacchi","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2016.11.001_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/aid.1991.7.295","article-title":"Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity","volume":"7","author":"Buckheit","year":"1991","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.antiviral.2016.11.001_bib8","series-title":"Camptothecins in cancer Therapy","author":"Burke","year":"2005"},{"key":"10.1016\/j.antiviral.2016.11.001_bib9","doi-asserted-by":"crossref","first-page":"33177","DOI":"10.1074\/jbc.M402062200","article-title":"The interaction between HIV-1 Gag and APOBEC3G","volume":"279","author":"Cen","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.11.001_bib10","doi-asserted-by":"crossref","first-page":"16546","DOI":"10.1074\/jbc.M109.085308","article-title":"Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G","volume":"285","author":"Cen","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.11.001_bib11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1128\/JVI.00676-12","article-title":"APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages","volume":"87","author":"Chaipan","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.11.001_bib12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nsmb1086","article-title":"APOBEC3G DNA deaminase acts processively 3'--> 5' on single-stranded DNA","volume":"13","author":"Chelico","year":"2006","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.antiviral.2016.11.001_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.virol.2008.04.017","article-title":"The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation","volume":"377","author":"Donahue","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2016.11.001_bib14","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1073\/pnas.0509922103","article-title":"A\u00a0dark yellow fluorescent protein (YFP)-based Resonance Energy-Accepting Chromoprotein (REACh) for Forster resonance energy transfer with GFP","volume":"103","author":"Ganesan","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2016.11.001_bib15","doi-asserted-by":"crossref","first-page":"11710","DOI":"10.1128\/JVI.01038-06","article-title":"Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication","volume":"80","author":"Guo","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.11.001_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature12884","article-title":"Structural basis for hijacking CBF-beta and CUL5 E3 ligase complex by HIV-1 Vif","volume":"505","author":"Guo","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2016.11.001_bib17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0092-8674(03)00423-9","article-title":"DNA deamination mediates innate immunity to retroviral infection","volume":"113","author":"Harris","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2016.11.001_bib18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1006\/bbrc.1998.9646","article-title":"Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins","volume":"252","author":"Hobbs","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2016.11.001_bib19","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1128\/JVI.06950-11","article-title":"Vif proteins of human and simian immunodeficiency viruses require cellular CBFbeta to degrade APOBEC3 restriction factors","volume":"86","author":"Hultquist","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.11.001_bib20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature10693","article-title":"Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection","volume":"481","author":"Jager","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2016.11.001_bib21","first-page":"1465","article-title":"Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity","volume":"49","author":"Jaxel","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2016.11.001_bib22","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1473-3099(13)70043-4","article-title":"The search for an HIV cure: tackling latent infection","volume":"13","author":"Kent","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.11.001_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1742-4690-4-48","article-title":"Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions","volume":"4","author":"Khan","year":"2007","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2016.11.001_bib24","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.celrep.2015.10.068","article-title":"Identification of the HIV-1 Vif and human APOBEC3G protein interface","volume":"13","author":"Letko","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.antiviral.2016.11.001_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1128\/JVI.01344-09","article-title":"The range of human APOBEC3H sensitivity to lentiviral Vif proteins","volume":"84","author":"Li","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.11.001_bib26","doi-asserted-by":"crossref","first-page":"32065","DOI":"10.1074\/jbc.M703423200","article-title":"APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription","volume":"44","author":"Li","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.11.001_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/molecules15010138","article-title":"The anti-HIV actions of 7- and 10-substituted camptothecins","volume":"15","author":"Li","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.antiviral.2016.11.001_bib28","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cub.2004.06.050","article-title":"APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in\u00a0vivo","volume":"14","author":"Liddament","year":"2004","journal-title":"Curr. Biol. CB"},{"key":"10.1016\/j.antiviral.2016.11.001_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature01709","article-title":"Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts","volume":"424","author":"Mangeat","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2016.11.001_bib30","doi-asserted-by":"crossref","first-page":"17259","DOI":"10.1074\/jbc.M602413200","article-title":"A\u00a0zinc-binding region in Vif binds Cul5 and determines cullin selection","volume":"281","author":"Mehle","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.11.001_bib31","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/nar\/gkp1009","article-title":"HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation","volume":"38","author":"Mercenne","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2016.11.001_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1742-4690-4-81","article-title":"The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G","volume":"4","author":"Miller","year":"2007","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2016.11.001_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/aid.1998.14.39","article-title":"9-Nitrocamptothecin inhibits tumor recrosis factor-mediated activation of human immunodeficiency virus type 1 and enhances apoptosis in a latently infected T cell clone","volume":"14","author":"Moulton","year":"1998","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.antiviral.2016.11.001_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2148-12-71","article-title":"An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals","volume":"12","author":"Munk","year":"2012","journal-title":"BMC Evol. Biol."},{"key":"10.1016\/j.antiviral.2016.11.001_bib35","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/nbt.1496","article-title":"Small-molecule inhibition of HIV-1 Vif","volume":"26","author":"Nathans","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2016.11.001_bib36","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/JVI.72.4.2855-2864.1998","article-title":"Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1","volume":"72","author":"Platt","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.11.001_bib37","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1128\/AAC.01324-07","article-title":"Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent","volume":"52","author":"Ptak","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.11.001_bib38","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1093\/nar\/gkq174","article-title":"Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction","volume":"38","author":"Refsland","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2016.11.001_bib39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cell.2013.09.044","article-title":"An integrated overview of HIV-1 latency","volume":"155","author":"Ruelas","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2016.11.001_bib40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.tibs.2014.07.001","article-title":"Structural insights for HIV-1 therapeutic strategies targeting Vif","volume":"39","author":"Salter","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.antiviral.2016.11.001_bib41","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature00939","article-title":"Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein","volume":"418","author":"Sheehy","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2016.11.001_bib42","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1371\/journal.ppat.0030015","article-title":"Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H","volume":"3","author":"Soros","year":"2007","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2016.11.001_bib43","doi-asserted-by":"crossref","first-page":"15387","DOI":"10.1073\/pnas.242259599","article-title":"The mechanism of topoisomerase I poisoning by a camptothecin analog","volume":"99","author":"Staker","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2016.11.001_bib44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1097-2765(03)00353-8","article-title":"HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by impairing both its translation and intracellular stability","volume":"12","author":"Stopak","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.antiviral.2016.11.001_bib45","doi-asserted-by":"crossref","first-page":"35822","DOI":"10.1074\/jbc.M405761200","article-title":"Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs","volume":"279","author":"Svarovskaia","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.11.001_bib46","doi-asserted-by":"crossref","first-page":"e1002684","DOI":"10.1371\/journal.pcbi.1002684","article-title":"Stochastic simulations suggest that HIV-1 survives close to its error threshold","volume":"8","author":"Tripathi","year":"2012","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.antiviral.2016.11.001_bib47","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.antiviral.2016.11.001_bib48","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1128\/JVI.02318-09","article-title":"Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif","volume":"84","author":"Walker","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.11.001_bib49","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1021\/ja00968a057","article-title":"Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata1,2","volume":"88","author":"Wall","year":"1966","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2016.11.001_bib50","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1006\/meth.1997.0481","article-title":"p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents","volume":"12","author":"Wehrly","year":"1997","journal-title":"Methods"},{"key":"10.1016\/j.antiviral.2016.11.001_bib51","doi-asserted-by":"crossref","first-page":"7135","DOI":"10.1128\/JVI.00031-10","article-title":"Dissection of the HIV Vif interaction with human E3 ubiquitin ligase","volume":"84","author":"Wolfe","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.11.001_bib52","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.drudis.2012.12.008","article-title":"Targeting HIV latency: pharmacologic strategies toward eradication","volume":"18","author":"Xing","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.antiviral.2016.11.001_bib53","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1074\/jbc.M004895200","article-title":"The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle","volume":"276","author":"Yang","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.11.001_bib54","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nsmb758","article-title":"Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome","volume":"11","author":"Yu","year":"2004","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.antiviral.2016.11.001_bib55","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1126\/science.1089591","article-title":"Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex","volume":"302","author":"Yu","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2016.11.001_bib56","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.41.5.977","article-title":"Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I","volume":"41","author":"Zhang","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.11.001_bib57","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature10718","article-title":"T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216303345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216303345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T07:10:41Z","timestamp":1718867441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216303345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":57,"alternative-id":["S0166354216303345"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.11.001","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}